This Article Full Text Full Text (PDF) All Versions of this Article: 90/6/3510    most recent Author Manuscript (PDF) Submit a related Letter to the Editor View responses Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Franchimont, D. Articles by Van Gossum, A. Search for Related Content PubMed PubMed Citation Articles by Franchimont, D. Articles by Van Gossum, A. Related Collections Neuroendocrinology and Pituitary Metabolism

Impact of Infliximab on Serum Leptin Levels in Patients with Crohn’s Disease

Laboratory of Experimental Gastroenterology and Department of Gastroenterology (D.F., S.R., T.G., E.Q., M.-C.G., J.D., A.V.G.), Erasme University Hospital, Brussels 1070, Belgium; and Division of Gastroenterology (D.F., Y.T.), Montreal General Hospital, McGill University, Montreal, Quebec, Canada H3A 1A4

Address all correspondence and requests for reprints to: Denis Franchimont, M.D., Ph.D., Division of Gastroenterology, Montreal General Hospital, McGill University, 1650 Cedar Avenue, D7.102, Montreal, Quebec, Canada H3A 1A4. E-mail: denis.franchimont{at}mcgill.ca.

Objectives: In mice, body weight is regulated by adipocyte-derived leptin. TNF is a critical mediator of inflammation-induced cachexia in Crohn’s disease (CD). The regulation of leptin by TNF is poorly understood in CD. Pharmacological neutralization of TNF with infliximab offers a unique opportunity to study TNF-mediated regulation of leptin in CD patients.

Methods: We prospectively followed up CD patients treated with infliximab (n = 20). Body composition was assessed before and after treatment at 1 and 4 wk. Serum leptin, IL-6, soluble TNF receptor type II, and soluble intercellular antiadhesion molecule-1 levels were measured as well as cholesterol levels and free urinary cortisol. Because methylprednisolone (MP) increases leptin production in vivo, CD patients treated with MP (n = 9) were studied separately as a positive control group.

Results: Infliximab induced clinical remission and a significant decrease in C-reactive protein (P < 0.01) and IL-6 (P < 0.05) levels in all CD patients and increased body weight (P = 0.013) at 4 wk. Leptinemia was significantly increased after infliximab administration at 1 wk (P = 0.014) and 4 wk (P < 0.001). This increase in serum leptin occurred early at 1 wk, when no significant weight and fat mass changes could be observed and was associated with the down-regulation of TNF-regulated mediators, soluble TNF receptor type II (P = 0.015), and soluble intercellular antiadhesion molecule-1 (P = 0.007). Moreover, infliximab increased cholesterol levels at 1 wk (P = 0.001). Twenty-four-hour cortisol secretion was not altered by infliximab. Leptinemia increased at 1 wk after MP administration (P = 0.028).

Conclusion: Infliximab increases leptinemia in CD. This study suggests that TNF exerts major inhibitory actions on leptin production in CD patients.

eLetters: